Tenofovir Af + Emtricitabine + Bictegravir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Bictegravir-50 mg + Emtricitabine-200 mg + TAF-25 mg
Reference Brands: Biktarvy(EU & US)
Category:
Anti Viral
Biktarvy is a once-daily, complete HIV-1 treatment with Bictegravir, Emtricitabine, and TAF. FDA and EMA approved, it offers high resistance protection and improved kidney and bone safety—no booster required.
Tenofovir AF + Emtricitabine + Bictegravir is available in Tablet
and strengths such as Bictegravir-50 mg + Emtricitabine-200 mg + TAF-25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tenofovir AF + Emtricitabine + Bictegravir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tenofovir AF + Emtricitabine + Bictegravir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Biktarvy is a complete, once-daily antiretroviral therapy for HIV-1 infection, combining Bictegravir 50 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 25 mg in a single tablet. Approved by both the FDA and EMA, Biktarvy is indicated for adults and pediatric patients (≥2 years, ≥14 kg) who are treatment-naïve or virologically suppressed. Bictegravir, a potent integrase inhibitor, offers a high barrier to resistance and does not require boosting agents. TAF enhances renal and bone safety over older TDF-based regimens. Biktarvy simplifies HIV management, supporting long-term viral suppression and patient adherence through convenient once-daily dosing, with or without food.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing